Document:

Exhibit

Confidential Materials Omitted – To be filed separately with the
Securities and Exchange Commission upon request.  Double asterisks denote omissions.
 Exhibit 10.1

	
										
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	2

	2. AMENDMENT/MODIFICATION NO.  
P00017
	3.     EFFECTIVE DATE 
06/13/2019
	4. REQUISITION/PURCHASE REQ NO.  
OS242076
	5. PROJECT NO. (If applicable) 

	6. ISSUED BY   CODE
	ASPR-BARDA
	7. ADMINISTERED BY (If other than Item 6)    CODE
	ASPR-BARDA02

	ASPR-BARDA 
200 Independence Ave., S.W. 
Room 640-G 
Washington DC 20201
	US DEPT OF HEALTH & HUMAN SERVICES 
ASST SEC OF PREPAREDNESS & RESPONSE 
ACQ MANAGEMENT, CONTRACTS, & GRANTS 
O’NEILL HOUSE OFFICE BUILDING 
Washington DC 20515

	8.     NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) 
	(x)
	9A. AMENDMENT OF SOLICITATION NO.

	EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303 
Attn:  DIANA 
EMERGENT BIODEFENSE OPERATIONS LANS 
3500 N MARTIN LUTHER KING JR BLVD 
LANSING MI 489062933
	 
	 

	 
	9B. DATED (SEE ITEM 11)

	 
	 

	x
	10A. MODIFICATION OF CONTRACT/ORDER NO.

	 
	HHSD200201792634C

	 
	10B. DATED (SEE ITEM 13)

	CODE    330303
	FACILITY CODE
	 
	12/08/2016

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	 The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers  is extended,  is not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning _________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or 
 
(c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.  If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)      Net Increase:   $27,927,000.00
See Schedule 

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.   
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	 
	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  
FAR 52.217-7 Option for Increased Quantity – Separately Priced Line Item

	 
	D. OTHER (Specify type of modification and authority)  

	E. IMPORTANT:  Contractor    is not,  is required to sign this document and return ____1____ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Tax ID Number: [**] 
DUNS Number: [**] 
The purpose of this modification is to:

1. Order an increased quantity of [**] doses of BioThrax [**] year product at a unit price of $[**] per dose for a total cost of $27,927,000.00.

2. Accordingly, total contract value is hereby increased from $492,321,363.90 by $27,927,000.00 to read $520,248,368.90.

3. This modification supersedes the Authorization to Proceed dated June 13, 2019. Continued...

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Michael Mann, Sr. Manager Comm. Ops.
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) 
Natasha Y. Rowland 

	15B. CONTRACTOR/OFFEROR

/s/ J. Michael Mann II   
(Signature of person authorized to sign)
	15C. DATE SIGNED

9 Jul 19
	16B. UNITED STATES OF AMERICA
By

/s/ Natasha Y. Rowland   
(Signature of Contracting Officer)
	16C. DATE SIGNED

7/9/2019

	 
	 
	 
	 

NSN 7540-01-152-8070    STANDARD FORM 30 (Rev. 10-83)
Previous edition unusable    Sponsored by GSA
FAR (48 CFR) 53.243

	
									
	CONTINUATION SHEET
	REFERENCE NO. OF DOCUMENT BEING CONTINUED
HHSD200201792634C/P00017
	PAGE OF

	2
	2

	NAME OF OFFEROR OR CONTRACTOR
EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303

	ITEM No. 
(A)
	SUPPLIES/SERVICES 
(B)
	QUANTITY 
(C)
	UNIT 
(D)
	UNIT PRICE 
(E)
	AMOUNT 
(F)

	

3
	4.     No further changes.
Delivery Location Code: HHS
HHS
200 Independence Avenue, SW
Washington DC 20201 US

FOB: Origin
Period of Performance: [**] to [**]

Change Item 3 to read as follows (amount shown is the obligated amount):

Optional Line Item 0003
BioThrax  [**] product 
Expiry dating upon date of delivery: 
No less than [**] Months and no more than [**] months for [**]-year product at a unit price of [**]

Quantity: [**]
Unit Price: [**]
Total Value: $27,927,000.00

Total dollar value ordered under Item 3 is increased by $27,927,000.00 from $[**] to $[**].

Delivery Address: Contractor’s Facility

Delivery is estimated to occur by NLT [**]

Amount: $[**]
Accounting Info: 
[**] Appr. Yr.: 2019 CAN: [**]
Object Class: 26402
Funded: $0.00

Amount: $[**]
Accounting Info:
[**] Appr. Yr.: 2019 CAN: [**]
Object Class: 26402
Funded: $0.00

Amount: $27,927,000.00
Accounting Info: 
[**] Appr. Yr.: 2019 CAN: 199SNS1
Object Class: 26402
Funded: $27,927,000.00

	 
	 
	 
	

$27,927,000.00

NSN 7540-01-152-8067    OPTIONAL FORM 336 (4-86)
Sponsored by GSA
FAR (48 CFR) 53.110Exhibit

EXHIBIT 10.2

FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 27, 2019, among EMERGENT BIOSOLUTIONS INC., a Delaware corporation (the “Borrower”), the Guarantors (as defined in the Credit Agreement referred to below) party hereto, the Lenders party hereto (the “Consenting Lenders”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, as administrative agent (the “Administrative Agent”). Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings provided such terms in the Credit Agreement referred to below.
W I T N E S S E T H:
WHEREAS, the Borrower, the lenders party thereto from time to time (the “Lenders”) and the Administrative Agent have entered into that certain Amended and Restated Credit Agreement, dated as of October 15, 2018 (as amended, supplemented or otherwise modified prior to the date hereof, the “Existing Credit Agreement”; the Existing Credit Agreement, as amended by this Amendment, the “Credit Agreement”);
WHEREAS, the Borrower has requested, and subject to the terms and conditions set forth herein, the Administrative Agent and the Consenting Lenders have agreed, to certain amendments to the Existing Credit Agreement as more specifically set forth herein;
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is agreed as follows: 
SECTION 1.Amendments to Existing Credit Agreement.  Effective as of the Amendment Effective Date (as defined in Section 2 below) and subject to the terms and conditions set forth herein and in reliance upon the representations and warranties set forth herein, the Existing Credit Agreement is hereby amended as follows:
(a)    Article I of the Existing Credit Agreement is hereby amended by adding the following defined terms in appropriate alphabetical order:
“Covenant Relief Period” means the period commencing with the First Amendment Effective Date and ending on the date that the Borrower provides the financial statements referred to in Section 8.1(a) for the fiscal year ended December 31, 2019, together with a duly completed Compliance Certificate for such period pursuant to Section 8.2(a) demonstrating compliance with the financial covenants set forth in Section 9.11.
“First Amendment Effective Date” means June 27, 2019.
“PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.
(b)    Article I of the Existing Credit Agreement is hereby amended by adding the following new Section 1.16 thereto and in connection therewith the table of contents shall be amended to include a reference to “SECTION 1.16 Divisions”:
“SECTION 1.16   Divisions.  For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.”
(c)    Section 5.13(a) of the Existing Credit Agreement is hereby amended by adding the parenthetical “(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in Section 9.11(b))” immediately following the reference to “Section 9.11” in proviso (B) of such Section.
(d)    Section 9.2 of the Existing Credit Agreement is hereby amended by adding the parenthetical “(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in Section 9.11(b))” immediately following the reference to “Section 9.11” in clause (g)(iv)(A) of such Section.
(e)    Section 9.3 of the Existing Credit Agreement is hereby amended by adding the parenthetical “(without giving effect to the increased maximum Consolidated Net Leverage Ratio levels permitted during the Covenant Relief Period set forth in Section 9.11(b))” immediately following the reference to “Section 9.11(b)” in clause (h)(ii)(A) of such Section.
(f)    Section 9.6 of the Existing Credit Agreement is hereby amended by replacing the proviso at the end of clause (d) of such Section with “; provided that the aggregate amount of Restricted Payments made pursuant to this Section 9.6(d) shall not exceed (x) $100,000,000 per calendar year and (y) $25,000,000 during the Covenant Relief Period;”.
(g)    Section 9.11 of the Existing Credit Agreement is hereby amended by (i) replacing the word “Permit” in the first sentence of such Section with “Subject to the sentence below during the Covenant Relief Period, permit” and (ii) adding the following paragraph to the end of clause (b) of such Section as follows:
“Notwithstanding any of the foregoing, the maximum Consolidated Net Leverage Ratio permitted pursuant to Section 9.11(b) during the Covenant Relief Period as of the last day of the applicable Measurement Period of the Borrower shall be (x) 4.95 to 1.00 for the fiscal quarter ended June 30, 2019 and (y) 4.75 to 1.00 for the fiscal quarter ended September 30, 2019, after which the maximum Consolidated Net Leverage Ratio permitted pursuant to this Section 9.11(b) shall be subject to the levels set forth in the table above.” 
(h)    Article XII of the Existing Credit Agreement is hereby amended by adding the following new Section 12.26 thereto and in connection therewith the table of contents shall be amended to include a reference to “SECTION 12.26 Acknowledgement Regarding Any Supported QFCs”:
“SECTION 12.26   Acknowledgement Regarding Any Supported QFCs.  To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedge Agreements or any other agreement or instrument that is a QFC (such support, “QFC Credit Support” and, each such QFC, a “Supported QFC”), the parties acknowledge and agree as follows with respect to the resolution power of the FDIC under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the “U.S. Special Resolution Regimes”) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States):
(a)    In the event a Covered Entity that is party to a Supported QFC (each, a “Covered Party”) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.  
(b)    As used in this Section 12.26, the following terms have the following meanings:
“BHC Act Affiliate” of a party means an “affiliate” (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.
“Covered Entity” means any of the following:
		
	(i)
	a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

		
	(ii)
	a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

		
	(iii)
	a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.
“QFC” has the meaning assigned to the term “qualified financial contract” in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).”
SECTION 2.    Conditions of Effectiveness of Amendment.  This Amendment, and the amendments set forth in Section 1 above, shall become effective on the date (such date, the “Amendment Effective Date”) when the Administrative Agent shall have received this Amendment, duly executed by a Responsible Officer of the Borrower, the Guarantors existing as of the Amendment Effective Date, the Administrative Agent and the Required Lenders.
SECTION 3.    Representations and Warranties. To induce the Administrative Agent and the Lenders to enter into this Amendment, each Credit Party represents and warrants to the Administrative Agent and the Lenders on and as of the Amendment Effective Date that, in each case:
(a)    the representations and warranties of each Credit Party set forth in the Credit Agreement and in each other Loan Document to which it is a party are true and correct in all material respects on and as of the Amendment Effective Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date; provided that any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates;  
(b)    no Default or Event of Default has occurred and is continuing;
(c)    it has all requisite power and authority and has taken all necessary corporate and other action to authorize the execution, delivery and performance of this Amendment and each other document executed in connection herewith to which it is a party in accordance with their respective terms and the transactions contemplated hereby; and
(d)    this Amendment and each other document executed in connection herewith has been duly executed and delivered by the duly authorized officers of each Credit Party, and each such document constitutes the legal, valid and binding obligation of each such Credit Party, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principals of equity.
SECTION 4.    Reference to and Effect on the Credit Agreement and the Loan Documents.   Except as expressly provided herein, the Existing Credit Agreement and the other Loan Documents shall remain unmodified and in full force and effect.  This Amendment shall not be deemed (a) to be a waiver of, or consent to, or a modification or amendment of, any other term or condition of the Existing Credit Agreement or any other Loan Document other than as expressly set forth herein, (b) to prejudice any right or rights which the Administrative Agent or the Lenders may now have or may have in the future under or in connection with the Existing Credit Agreement or the other Loan Documents or any of the instruments or agreements referred to therein, as the same may be amended, restated, supplemented or modified from time to time, or (c) to be a commitment or any other undertaking or expression of any willingness to engage in any further discussion with the Borrower, any of its Subsidiaries or any other Person with respect to any other waiver, amendment, modification or any other change to the Existing Credit Agreement or the Loan Documents or any rights or remedies arising in favor of the Lenders or the Administrative Agent, or any of them, under or with respect to any such documents.  References in the Credit Agreement to “this Agreement” (and indirect references such as “hereunder”, “hereby”, “herein”, “hereof” or other words of like import) and in any Loan Document to the “Credit Agreement” shall be deemed to be references to the Existing Credit Agreement as modified hereby.
SECTION 5.    Further Assurances.  Each Credit Party agrees to, to the extent required by the Loan Documents, make, execute and deliver all such additional and further acts, things, deeds, instruments and documents as the Administrative Agent may reasonably require for the purposes of implementing or effectuating the provisions of this Amendment and the other Loan Documents.  
SECTION 6.    Acknowledgement and Reaffirmation. Each Credit Party (a) consents to this Amendment and agrees that the transactions contemplated by this Amendment shall not limit or diminish the obligations of such Person under, or release such Person from any obligations under, any of the Loan Documents to which it is a party (as amended pursuant to this Amendment), (b) confirms and reaffirms its obligations under each of the Loan Documents to which it is a party (as amended pursuant to this Amendment) and (c) agrees that each of the Loan Documents to which it is a party (as amended pursuant to this Amendment) remains in full force and effect and is hereby ratified and confirmed.
SECTION 7.    Costs and Expenses. The Borrower hereby reconfirms its obligations pursuant to Section 12.3(a) of the Credit Agreement to pay and reimburse the Administrative Agent in accordance with the terms thereof.
SECTION 8.    Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
SECTION 9.    Counterparts. This Amendment may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which counterparts when executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. Delivery by facsimile or electronic transmission of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment.
SECTION 10.    Entire Agreement.  This Amendment is the entire agreement, and supersedes any prior agreements and contemporaneous oral agreements, of the parties concerning its subject matter.  This Amendment is a Loan Document and is subject to the terms and conditions of the Credit Agreement.
SECTION 11.    Successors and Assigns.  This Amendment shall be binding on and inure to the benefit of the parties hereto and their successors and permitted assigns.
[The remainder of this page is intentionally left blank.]

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Amendment as of the date first above written.

EMERGENT BIOSOLUTIONS INC., as Borrower

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   EVP, Chief Financial Officer and Treasurer

CANGENE BIOPHARMA LLC, as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   Treasurer    
EMERGENT BIODEFENSE OPERATIONS LANSING LLC, as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   Treasurer     
EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC, as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   Executive Manager 
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC., as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl 
Title:   Treasurer     
    

EMERGENT INTERNATIONAL INC., as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   Treasurer     
EMERGENT TRAVEL HEALTH INC. (FORMERLY
KNOWN AS PAXVAX, INC.), as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   CFO and Treasurer     
ADAPT PHARMA INC., as Guarantor

By: /s/ Richard S. Lindahl    
Name: Richard S. Lindahl
Title:   Treasurer     

WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender, Issuing Lender and Lender

By: /s/ Kent S. Davis
       Name: Kent S. Davis
 Title:   Managing Director 

JPMORGAN CHASE BANK, N.A., as Lender

By: /s/ Anthony Galea        
Name: Anthony Galea
Title:   Executive Director 

PNC BANK, NATIONAL ASSOCIATION, as Lender

By: /s/ Eric H. Williams        
Name: Eric H. Williams 
Title:   Senior Vice President 

ROYAL BANK OF CANADA, as Lender

By: /s/ Steven T. Bachman    
Name: Steven T. Bachman
Title:   Authorized Signatory 

BMO HARRIS BANK, N.A., as Lender

By: /s/ Eric Oppenheimer           
Name: Eric Oppenheimer 
Title:   Managing Director 

CAPITAL ONE, N.A., as Lender

By: /s/ Jeffrey Schaal         
       Name: Jeffrey Schaal 
Title:   Duly Authorized Signatory 

CITIZENS BANK, N.A., as Lender

By: /s/ Jack J. Euston
Name:  Jack J. Euston
Title:    Vice President 

MUFG UNION BANK, N.A., as Lender

By: /s/ Teuta Ghilaga
Name:  Teuta Ghilaga
Title:    Director 

REGIONS BANK, as Lender

By: /s/ Ned Spitzer
Name: Ned Spitzer
Title:   Managing Director 

SUNTRUST BANK, as Lender

By: /s/ Katherine Bass
Name:  Katherine Bass 
Title:    Director 

THE HUNTINGTON NATIONAL BANK, as Lender

By: /s/ Joseph A. Miller 
Name: Joseph A. Miller 
Title:   Managing Director 

BANK OF AMERICA, N.A., as Lender

By: /s/ H. Hope Walker 
Name: H. Hope Walker 
Title:   Senior Vice President 

BANK OF THE WEST, as a Lender

By: /s/ Harry Yergey
Name: Harry Yergey
Title:   Managing Director 

By: /s/ Michael Weinert 
Name: Michael Weinert 
Title:   Director 

DNB CAPITAL LLC, as a Lender

By: /s/ Kristi Birkeland Sorensen 
Name: Kristi Birkeland Sorensen 
Title:   Senior Vice President
                  Head of Corporate Banking

By: /s/ Devan Patel
Name: Devan Patel 
Title:   Vice President 

FIRST NATIONAL BANK, as a Lender

By: /s/ Douglas T. Brown
Name: Douglas T. Brown 
Title:   Senior Vice President 

FIFTH THIRD BANK, as a Lender

By: /s/ Vera B. McEvoy 
Name: Vera B. McEvoy
Title:    Director II

HSBC BANK USA, N.A., as a Lender

By: /s/ Reed R. Menefee 
Name: Reed R. Menefee
Title:   Managing Director 

MORGAN STANLEY BANK, as a Lender

By: /s/ Jackson Eng
Name: Jackson Eng 
Title:   Authorized Signatory 

 

TD BANK, N.A., as a Lender

By: /s/ Shivani Agarwal 
Name: Shivani Agarwal 
Title:   Senior Vice President 

U.S. BANK NATIONAL ASSOCIATION, as a Lender

By: /s/ Tom Priedeman
Name: Tom Priedeman 
Title:   Vice President 

117427862_4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]